Amarin Corp Plc (AMRN):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Amarin Corp Plc (AMRN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10024
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:75
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アイルランド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Amarin Corp Plc (Amarin) is a biopharmaceutical company which develops and commercializes medicines for cardiovascular domain. The company’s lead product Vascepa (icosapent ethyl) is a US FDA approved single-molecule prescription capsule used as an adjunct to diet, for the reduction of triglyceride levels in adult patients with severe hypertriglyceridemia and high triglyceride levels or mixed dyslipidemia. The company is also evaluating Vascepa as an add-on therapy to reduce major cardiovascular events in an at-risk patient population on statin therapy. Amarin markets the product in the US through wholesalers and specialty pharmacy providers. The company has subsidiaries in Ireland, the US, Scotland and Israel. Amarin is headquartered at Dublin, Ireland.

Amarin Corp Plc (AMRN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Amarin Corp Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Amarin Corp Plc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Amarin and HLS Therapeutics Enter into Agreement 11
Amarin Enters into Development Agreement with Eddingpharm 12
Amarin And Kowa Pharm Enter Into Co-Promotion Agreement For Vascepa Capsules 13
Licensing Agreements 15
Amarin Enters into Licensing Agreement with Mochida Pharma 15
Equity Offering 16
Amarin Raises USD65 Million in Public Offering of American Depositary Shares 16
Amarin Files Registration Statement for Public Offering of ADS 17
Amarin Announces Underwriter’s Exercise of Over-Allotment Option of Public Offering of ADS for USD69 Million 18
Amarin to Raise USD53 Million in Private Placement of American Depositary Shares 20
Amarin Completes Public Offering Of Shares For US$121.5 Million 21
Debt Offering 23
Corsicanto II Designated Activity (Amarin) Raises USD30 Million in Exchangeable Senior Notes 23
Amarin to Raise USD31.3 Million in Private Placement of 3.5% Notes Due 2032 24
Amarin Corporation Completes Private Placement For US$100 Million 25
Amarin Completes Private Placement Of 3.5% Exchangeable Senior Notes Due 2032 For US$150 Million 26
Acquisition 27
Teva Pharma Rumored To Acquire Amarin 27
Amarin Corp Plc – Key Competitors 28
Amarin Corp Plc – Key Employees 29
Amarin Corp Plc – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Financial Announcements 31
Nov 01, 2018: Amarin reports third quarter 2018 financial results and provides update on operations 31
Aug 01, 2018: Amarin reports second quarter 2018 financial results and provides update on operations 35
May 02, 2018: Amarin Reports First Quarter 2018 Financial Results and Provides Update on Operations 38
Feb 27, 2018: Amarin Reports Announces Fourth Quarter and Full Year 2017 Financial Results 40
Nov 01, 2017: Amarin Reports Third Quarter 2017 Financial Results and Provides Update on Operations 45
Aug 02, 2017: Amarin Reports Second Quarter 2017 Financial Results and Provides Update on Operations 47
May 03, 2017: Amarin reports lower Q1 net loss, re-affirms annual guidance 50
Feb 28, 2017: Amarin Reports Record Fourth Quarter and Full Year 2016 Financial Results and Provides Update on Operations 51
Jan 05, 2017: Amarin announces revenue forecast for 2017 54
Jan 05, 2017: Amarin Provides Preliminary 2016 Results and 2017 Outlook 56
Corporate Communications 58
Apr 23, 2018: Amarin Announces Promotes Aaron Berg To Chief Commercial Officer 58
Product News 59
06/12/2017: Vascepa (Icosapent Ethyl) Showed Reductions in Potentially Atherogenic Lipid Parameters in Statin-Treated Women With Type 2 Diabetes and Persistent High Triglycerides 59
05/18/2017: Amarin Announces Expanded Research Relationships and Studies to Help Improve Cardiovascular Care 60
05/03/2017: Amarin Reports First Quarter 2017 Financial Results and Provides Update on Operations 61
03/16/2017: Amarin Reaches the Onset of Approximately 80% of the Target Aggregate Number of Primary Major Adverse Cardiovascular Events Within the REDUCE-IT Study 66
03/15/2017: Amarin Announces Publication of REDUCE-IT Cardiovascular Outcomes Study Rationale and Design in Clinical Cardiology 67
01/05/2017: Amarin Provides Preliminary 2016 Results and 2017 Outlook 68
Clinical Trials 70
Sep 13, 2017: Amarin Appoints Mark W. Salyer to New Position of Chief Commercial Officer 70
Aug 14, 2017: Amarin Provides Update on Vascepa 71
Other Significant Developments 73
Apr 04, 2018: Amarin Updates First Quarter Revenue Guidance, Reiterates Full Year Guidance and Updates on REDUCE-IT Cardiovascular Outcomes Study Progress and Vascepa Promotion Initiatives 73
Appendix 75
Methodology 75
About GlobalData 75
Contact Us 75
Disclaimer 75

List of Tables
Amarin Corp Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Amarin Corp Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Amarin Corp Plc, Deals By Therapy Area, 2012 to YTD 2018 9
Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Amarin and HLS Therapeutics Enter into Agreement 11
Amarin Enters into Development Agreement with Eddingpharm 12
Amarin And Kowa Pharm Enter Into Co-Promotion Agreement For Vascepa Capsules 13
Amarin Enters into Licensing Agreement with Mochida Pharma 15
Amarin Raises USD65 Million in Public Offering of American Depositary Shares 16
Amarin Files Registration Statement for Public Offering of ADS 17
Amarin Announces Underwriter’s Exercise of Over-Allotment Option of Public Offering of ADS for USD69 Million 18
Amarin to Raise USD53 Million in Private Placement of American Depositary Shares 20
Amarin Completes Public Offering Of Shares For US$121.5 Million 21
Corsicanto II Designated Activity (Amarin) Raises USD30 Million in Exchangeable Senior Notes 23
Amarin to Raise USD31.3 Million in Private Placement of 3.5% Notes Due 2032 24
Amarin Corporation Completes Private Placement For US$100 Million 25
Amarin Completes Private Placement Of 3.5% Exchangeable Senior Notes Due 2032 For US$150 Million 26
Teva Pharma Rumored To Acquire Amarin 27
Amarin Corp Plc, Key Competitors 28
Amarin Corp Plc, Key Employees 29
Amarin Corp Plc, Subsidiaries 30

List of Figures
Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Amarin Corp Plc (AMRN):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • CDW Corporation:戦略・SWOT・企業財務分析
    CDW Corporation - Strategy, SWOT and Corporate Finance Report Summary CDW Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Insight Genetics Inc:医療機器:M&Aディール及び事業提携情報
    Summary Insight Genetics Inc (Insight Genetics) is a molecular diagnostic company which discovers, develops and commercializes companion diagnostics. The company offers assays for triple negative breast cancer; and a suite of molecular tests including anaplastic lymphoma kinase (ALK), ROS1 and RET f …
  • BASF Corp:企業のM&A・事業提携・投資動向
    BASF Corp - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's BASF Corp Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capita …
  • Empire Electric Association Inc:企業の戦略的SWOT分析
    Empire Electric Association Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Argon Medical Devices Inc:医療機器:M&Aディール及び事業提携情報
    Summary Argon Medical Devices Inc (Argon) is a medical device company that manufactures and supplies products for the dialysis and others. The company provides arterial catheters, temporary pacing electrode trays, pulmonary artery and thermodilution catheters, and single lumen central venous cathete …
  • USG Corporation:企業の戦略・SWOT・財務情報
    USG Corporation - Strategy, SWOT and Corporate Finance Report Summary USG Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Albena AD Albena :企業の戦略・SWOT・財務情報
    Albena AD Albena - Strategy, SWOT and Corporate Finance Report Summary Albena AD Albena - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • PRA Health Sciences Inc (PRAH):企業の財務・戦略的SWOT分析
    Summary PRA Health Sciences Inc (PRA) is a contract research organization (CRO) which provides outsourced clinical development and data solution services. The company offers asset valuation, regulatory and drug development consulting, risk-based monitoring, site identification and selection, medical …
  • Ceylon Cold Stores PLC:企業の戦略・SWOT・財務情報
    Ceylon Cold Stores PLC - Strategy, SWOT and Corporate Finance Report Summary Ceylon Cold Stores PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Merge Healthcare Inc-医療機器分野:企業M&A・提携分析
    Summary Merge Healthcare Inc (Merge Technologies), a subsidiary of International Business Machines Corp is a medical technology company that offers advanced solutions specifically designed for healthcare. The company's solutions include interoperability, radiology, cardiology, orthopedics, clinical …
  • PetroChina Company Limited:企業の戦略・SWOT・財務分析
    PetroChina Company Limited - Strategy, SWOT and Corporate Finance Report Summary PetroChina Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Acciona SA (ANA):企業の財務・戦略的SWOT分析
    Acciona SA (ANA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Wabash Valley Power Association, Inc.:企業の戦略的SWOT分析
    Wabash Valley Power Association, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and maj …
  • John Menzies Plc:企業の戦略・SWOT・財務分析
    John Menzies Plc - Strategy, SWOT and Corporate Finance Report Summary John Menzies Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Insurance Australia Group Limited:企業の戦略・SWOT・財務情報
    Insurance Australia Group Limited - Strategy, SWOT and Corporate Finance Report Summary Insurance Australia Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Apartment Investment and Management Co:企業の戦略・SWOT・財務分析
    Apartment Investment and Management Co - Strategy, SWOT and Corporate Finance Report Summary Apartment Investment and Management Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • Tainergy Tech Co Ltd (4934):電力:M&Aディール及び事業提携情報
    Summary Tainergy Tech Co Ltd (Tainergy) is a renewable energy company that designs, develops, manufactures and markets solar energy products. The company provides products such as solar deionized water systems, multi-crystalline silicon solar cell, standard solar modules, solar module with build in …
  • WH Ireland Group Plc (WHI):企業の財務・戦略的SWOT分析
    WH Ireland Group Plc (WHI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • NN Group NV:企業の戦略・SWOT・財務情報
    NN Group NV - Strategy, SWOT and Corporate Finance Report Summary NN Group NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Jadranski naftovod dd (JNAF-R-A):企業の財務・戦略的SWOT分析
    Summary Jadranski naftovod dd (JANAF Plc) is an oil pipeline system managing company that operates crude oil transportation system and reloading and storage of crude oil and oil products. The company manages janaf system, an international crude oil transportation system. Its janaf systems consists o …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆